Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

FRESENIUS MEDICAL CARE AG & CO. KGAA

(FME)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Fresenius Medical Care : strengthens transplantation medicine

09/06/2021 | 08:42am EDT

Fresenius Medical Care expands capabilities at its Global Medical Office: As part of a holistic approach to kidney therapy, the company aims to play an active role in the field of kidney transplantation. To achieve this, Fresenius Medical Care has created the position of Head of Transplantation Medicine and appointed Dr. Benjamin Hippen (49), a US citizen, to fill the post. In this role, he will lead the company's worldwide efforts to expand access to and understanding of transplant medicine. Dr. Hippen is a distinguished general and transplant nephrologist. He previously served on the Board of Directors of InterWell Health in North America, a nephrology network in which Fresenius Medical Care participates.

Disclaimer

FMC - Fresenius Medical Care AG & Co. KGaA published this content on 06 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 September 2021 12:41:03 UTC.


© Publicnow 2021
All news about FRESENIUS MEDICAL CARE AG & CO. KGAA
11:06aEuropean ADRs Move Lower in Monday Trading
MT
10/07FMC FRESENIUS MEDICAL CARE AG & CO K : Jefferies maintains a Sell rating
MD
10/07FMC FRESENIUS MEDICAL CARE AG & CO K : NorldLB reiterates its Buy rating
MD
10/07Fresenius Medical Care AG & Co. KGaA acquired Sugerencias Medicas S.A.
CI
10/05FRESENIUS MEDICAL CARE : donates 250,000 euros to UNICEF - battle against COVID-19 pandemi..
AQ
10/05FMC FRESENIUS MEDICAL CARE AG & CO K : Barclays reiterates its Neutral rating
MD
09/30FRESENIUS SE & CO. KGAA : Release according to Article 41 of the WpHG [the German Securiti..
DJ
09/30FRESENIUS MEDICAL CARE AG & CO. KGAA : Release according to Article 41 of the WpHG [the Ge..
EQ
09/30FRESENIUS MEDICAL CARE AG & CO. KGAA : Release according to Article 41 of the WpHG [the Ge..
DJ
09/30FMC FRESENIUS MEDICAL CARE AG & CO K : JP Morgan gives a Sell rating
MD
More news
Analyst Recommendations on FRESENIUS MEDICAL CARE AG & CO. KGAA
More recommendations
Financials (USD)
Sales 2021 21 130 M - -
Net income 2021 1 267 M - -
Net Debt 2021 13 395 M - -
P/E ratio 2021 16,1x
Yield 2021 1,97%
Capitalization 20 826 M 20 828 M -
EV / Sales 2021 1,62x
EV / Sales 2022 1,52x
Nbr of Employees 123 538
Free-Float 67,8%
Chart FRESENIUS MEDICAL CARE AG & CO. KGAA
Duration : Period :
Fresenius Medical Care AG & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS MEDICAL CARE AG & CO. KGAA
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 19
Last Close Price 71,08 $
Average target price 81,13 $
Spread / Average Target 14,1%
EPS Revisions
Managers and Directors
Rice Powell Chief Executive Officer
Helen Giza Chief Financial Officer
Dieter Schenk Chairman-Supervisory Board
Olaf Schermeier CEO-Global Research & Development
Franklin W. Maddux Global Chief Medical Officer
Sector and Competitors